



(19) United States

(12) Patent Application Publication (10) Pub. No.: US 2008/0253990 A1 Steidler et al.

(43) **Pub. Date:** Oct. 16, 2008

(54) SELF-CONTAINING LACTOBACILLUS **STRAIN**

Lothar Steidler, Drongen (BE); (75) Inventors: Sabine Neirynck, Drongen (BE)

> Correspondence Address: TRASK BRITT P.O. BOX 2550 SALT LAKE CITY, UT 84110 (US)

(73) Assignee: UNIVERSITY COLLAGE COOK, CORK (IE)

(21) Appl. No.: 11/596,715

(22) PCT Filed: May 18, 2005

(86) PCT No.: PCT/EP05/52296

§ 371 (c)(1),

(2), (4) Date: Mar. 7, 2008

(30)**Foreign Application Priority Data**

May 18, 2004 (EP) 04102202.1

Publication Classification

(51)	Int. Cl.	
	A61K 47/00	(2006.01)
	C12N 1/21	(2006.01)
	A61K 38/20	(2006.01)
	A61P 1/00	(2006.01)

(52) **U.S. Cl.** **424/85.2**; 435/252.3; 514/772

ABSTRACT

The invention relates to a recombinant Lactobacillus strain, with limited growth and viability in the environment. More particularly, it relates to a recombinant *Lactobacillus* that can only survive in a medium where thymidine is present. By this strict dependency upon thymidine, thymidineless death is rapidly induced in this recombinant strain. A preferred embodiment is a Lactobacillus that may only survive in a host organism where thymidine is present, but cannot survive outside the host organism in absence of this medium compound. Moreover, the Lactobacillus strain can be transformed with prophylactic and/or therapeutic molecules and can, as such, be used to treat diseases such as, but not limited to, inflammatory bowel diseases.

